LIVER DISEASES

Michael TRAUNER

SITE

Toxicol Lett. 2022;368:33-46. In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assay. Brecklinghaus T, Albrecht W, Duda J, Kappenberg F, Gründler L, Edlund K, Marchan R, Ghallab A, Cadenas C, Rieck A, Vartak N, Tolosa L, Castell JV, Gardner I, Halilbasic E, Trauner M, Ullrich A, Zeigerer A, Demirci Turgunbayer Ö, Damm G, Seehofer D, Rahnenführer J, Hengstler JG. PubMed

J Intern Med. 2022;292:190-204. Current treatment of non-alcoholic fatty liver disease. Paternostro R, Trauner M. PubMed

Nat Rev Gastroenterol Hepatol. 2022;19:432-450. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Fuchs CD, Trauner M. PubMed

J Hepatol. 2022;77:71-83. Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. Ghallab A, Hassan R, Hofmann U, Friebel A, Hobloss Z, Brackhagen L, Begher-Tibbe B, Myllys M, Reinders J, Overbeck N, Sezgin S, Zühlke S, Seddek AL, Murad W, Brecklinghaus T, Kappenberg F, Rahnenführer J, González D, Goldring C, Copple IM, Marchan R, Longerich T, Vucur M, Luedde T, Urban S, Canbay A, Schreiter T, Trauner M, Akakpo JY, Olyaee M, Curry SC, Sowa JP, Jaeschke H, Hoehme S, Hengstler JG. PubMed

Gut. 2022;71:194-209. Novel therapeutic targets for cholestatic and fatty liver disease. Trauner M, Fuchs CD. PubMed

Hepatology. 2021;74:3497-3512. On the mechanisms of biliary flux. Vartak N, Drasdo D, Geisler F, Itoh T, P J Oude Elferink R, van de Graaf SFJ, Chiang J, Keitel V, Trauner M, Jansen P, Hengstler JG. PubMed

Hepatology. 2020;71:1750-1765. Monoacylglycerol Lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis. Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Baumgartner M, A H O Ronda O, Verkade HJ, Stojakovic T, Scharnagl H, Habib A, Zimmermann R, Lotersztajn S, Trauner M. PubMed

Liver Int. 2020;40:1366-1377. Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. Fuchs CD, Krivanec S, Steinacher D, Mlitz V, Wahlström A, Stahlman M, Claudel T, Scharnagl H, Stojakovic T, Marschall HU, Trauner M. PubMed

Contrast Media Mol Imaging. 2018;2018:8489709. Noninvasive monitoring of liver disease regression after Hepatitis C eradication using Gadoxetic acid-enhanced MRI. Haider L, Mandorfer M, Güngören Z, Reiberger T, Bastati N, Hodge JC, Chromy D, Trauner M, Herold C, Peck-Radosavljevic M, Ba-Ssalamah A. PubMed

J Lipid Res. 2018;59:1610-1619. Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice. Gautherot J, Claudel T, Cuperus F, Fuchs CD, Falguieres T, Trauner M. PubMed

J Hepatol. 2018;69:368-377.  Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. Pollheimer MJ, Racedo S, Mikels-Vigdal A, Marshall D, Bowlus C, Lackner C, Madl T, Karlsen TH, Hov JR, Lyman SK, Adamkewicz J, Smith V, Moreau E, Zollner G, Eide TJ, Stojakovic T, Scharnagl H, Gruber HJ, Stauber RE, Trauner M, Fickert P. PubMed

Abdom Radiol (NY). 2018;43:2963-2969. Imaging. [11C]acetate PET as a tool for diagnosis of liver steatosis. Nejabat M, Leisser A, Karanikas G, Wadsak W, Mitterhauser M, Mayerhöfer M, Kienbacher C, Trauner M, Hacker M, Haug AR. PubMed

Gut. 2018;67:1683-1691. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids. Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlström A, Ståhlman M, Thüringer A, Kashofer K, Stojakovic T, Marschall HU, Trauner M. PubMed

Hepatology. 2018;In press. Na+-taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, Oude Elferink RPJ, van de Graaf SFJ. PubMed

Annu Rev Pathol. 2018;13:321-350. Recent insights into the pathogenesis of Nonalcoholic Fatty Liver Disease. Arab JP, Arrese M, Trauner M. PubMed

Oncotarget. 2017;8:57109-57120. Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M. PubMed

Mol Pharmacol. 2017;92:401-413. Molecular mechanism of taurocholate transport by the Bile Salt Export Pump, an ABC transporter associated with intrahepatic cholestasis. Sohail MI, Schmid D, Wlcek K, Spork M, Szakács G, Trauner M, Stockner T, Chiba P. PubMed

Invest Radiol. 2017;52:462-469. Imaging. Effects of portal hypertension on Gadoxetic Acid-enhanced liver Magnetic Resonance: diagnostic and prognostic implications. Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, Ferlitsch A, Kaczirek K, Trauner M, Peck-Radosavljevic M, Wibmer AG. PubMed

J Hepatol. 2017;67:549-558. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. PubMed

Hepatology. 2017;65:1393-1404. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. PubMed

Oncotarget. 2016;2016;7:86985-86998. Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease. Lemberger UJ, Fuchs C, Karer M, Haas S, Stojakovic T, Schöfer C, Marschall HU, Wrba F, Taketo MM, Egger G, Trauner M, Österreicher CH. PubMed

J Hepatol. 2017;66:95-101. Metabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury. Fuchs CD, Paumgartner G, Wahlström A, Schwabl P, Reiberger T, Leditznig N, Stojakovic T, Rohr-Udilova N, Chiba P, Marschall HU, Trauner M. PubMed

Hepatology. 2017;65:350-362. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. PubMed

J Magn Reson Imaging. 2017;45:646-659. Imaging. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, Van Beers BE. PubMed

Invest Radiol. 2016;51:728-734. Imaging. Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using qualitative and quantitative parameters. Bastati N, Wibmer A, Tamandl D, Einspieler H, Hodge JC, Poetter-Lang S, Rockenschaub S, Berlakovich GA, Trauner M, Herold C, Ba-Ssalamah A. PubMed

J Pharm Sci. 2016;105:106-12. Imaging. Influence of 24-Nor-Ursodeoxycholic acid on hepatic disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography study in mice. Wanek T, Halilbasic E, Visentin M, Mairinger S, Römermann K, Stieger B, Kuntner C, Müller M, Langer O, Trauner M. PubMed

Radiology. 2015;277:104-13. Imaging. Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Ba-Ssalamah A, Antunes C, Feier D, Bastati N, Hodge JC, Stift J, Cipriano MA, Wrba F, Trauner M, Herold CJ, Caseiro-Alves F. PubMed

J Hepatol. 2015;62:S25-37.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. Beuers U, Trauner M, Jansen P, Poupon R. PubMed

Digestion. 2014;90:81-8. Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury. Zollner G, Thueringer A, Lackner C, Fickert P, Trauner M. PubMed

Drug Discov Today Technol. 2014;12:e87-94.  Pharmacological correction of misfolding of ABC proteins. Rudashevskaya EL, Stockner T, Trauner M, Freissmuth M, Chiba P. PubMed

Drug Metab Dispos. 2014;42:1423-31. Inflammatory bowel disease alters intestinal bile acid transporter expression. Jahnel J, Fickert P, Hauer AC, Högenauer C, Avian A, Trauner M. PubMed

Drug Metab Dispos. 2014;42:546-60. The role of canalicular ABC transporters in cholestasis. Cuperus FJ, Claudel T, Gautherot J, Halilbasic E, Trauner M. PubMed

Mol Aspects Med. 2014;37:57-76. Clinical application of transcriptional activators of bile salt transporters. Baghdasaryan A, Chiba P, Trauner M. PubMed

Digestion. 2012;86:244-9. Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. Marschall HU, Wagner M, Zollner G, Fickert P, Silbert D, Gustafsson U, Sahlin S, Trauner M. PubMed